SISaeed Izadi

Saeed Izadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saeed Izadi has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid generation of antibody conformational ensembles using machine learning

    by Pranav V. Rao, David Sommer, Darcy Davidson, Robert G. Alberstein, Jan Ludwiczak, Joseph Kleinhenz, Bodhi Vani, Eliott Park, Jae Hyeon Lee, Saeed Izadi, et al.

    We introduce Cadense, a generative framework for antibody ensemble prediction that produces diverse Fv structures from sequence, informed by conformational dynamics. While a valuable resource, static structure prediction provides only a single snapshot of dynamic proteins, whose motions influence their binding and other properties. This is particularly relevant for antibodies, an important class of molecules for drug discovery, where flexible complementarity determining region (CDR) loops are difficult to model with static approaches. Cadense addresses this gap by generating ensembles that match conformational and biophysical property distributions from molecular dynamics (MD), while reducing the computational burden from days of simulation to seconds of generation. We show Cadense ensembles can recover both apo and holo conformations of the same antibody and serve as effective input to physics-based docking, capturing the conformational flexibility important to properly model antibody–antigen interactions. Together, these results establish Cadense as a useful tool for antibody conformational ensemble generation with the promise to enable faster, dynamics-aware antibody design.

  • Open Access

    Local electrostatics governs tryptophan oxidation and enables rational stability engineering in antibodies

    by Sunidhi Lenka, Shrenik Mehta, Nicole Stephens, Franziska Seeger, Wei-Ching Liang, Andrew Watkins, Jonathan Zarzar, Negar Jafari, Rhyan Puno, Caleigh Azumaya, et al.

    Oxidation is a major degradation pathway in proteins with far-reaching implications in physiological functions and pathological conditions.1–9 Oxidative damage is thought to contribute to aging2 an...


  • Open Access

    Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies

    by Santosh Kumar Paidi, Julissa Ibrahim, Kateryna Stepurska, Jonathan Zarzar, Saeed Izadi, Erina Rude, Steven Luu, Daniel Kovner, Kelly O’COnnor, Karenna Bol, et al.

    1. The current era of biopharmaceutical development is characterized by a significant emphasis on monoclonal antibody (mAb) therapeutics and their subcutaneous delivery.1,2 These molecules have tra...

  • Open Access

    Fab–Fc and Fab–Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG 1 antibodies

    by Joel Heisler, Jennifer L. Hofmann, Zhenyu Tan, Jonathan Zarzar, Saeed Izadi, Paul J. Carter

    The variable domains in Fab regions are well-established contributors to high concentration viscosity of IgG, primarily through charge and hydrophobic interactions. In contrast, the roles of the Fc and the number of self-interacting sites (valency) are less well understood. Here, we investigate the relative contributions of Fab–Fab and Fab–Fc interactions to high concentration viscosity for a diverse panel of 20 IgG 1 antibodies, by rheometry, coarse-grained simulations, and molecular surface property analysis. Strikingly, fragmentation of IgG 1 into F(ab′) 2 plus Fc reduced viscosity (−11 to −93%) for all antibodies tested, demonstrating prevalent contributions of Fc to viscosity. Coarse-grained simulations with one site per Fab and two sites per Fc qualitatively tracked trends in experimental rheometry data for 20 parental antibodies and their fragments. In these simulations Fab–Fab and Fab–Fc interaction strengths were independently varied to capture possible interaction differences arising from parental sequences or any mutations. These coarse-grained simulations suggest that Fab–Fc attractions generate branched IgG 1 networks and disproportionately larger clusters relative to Fab–Fab interactions of comparable strength. This study suggests that a four-site self-interaction model, previously proposed for a single antibody (omalizumab), is broadly applicable to diverse IgG 1 . Beyond well-established variable domain engineering, this self-interaction model predicts that Fc engineering may reduce IgG 1 viscosity, a much sought after goal to enable subcutaneous delivery. Clinically validated Fc mutations are demonstrated here to substantially reduce the viscosity for multiple IgG 1 (−33 to −91% reduction, n = 6), supporting this emerging antibody design concept.


  • Open Access

    Rational design of oxidation-resistant antibodies through local electrostatic modulation

    by Sunidhi Lenka, Shrenik Mehta, Nicole Stephens, Franziska Seeger, Wei-Ching Liang, Andrew Watkins, Jonathan Zarzar, Negar Jafari, Rhyan Puno, Caleigh Azumaya, et al.

    Oxidation is a significant degradation pathway in proteins, particularly therapeutic antibodies, that can impair function, efficacy, and stability. Understanding the sequence and structural factors that drive oxidation susceptibility is critical for incorporating chemical stability into early-stage antibody design. Here, we present a machine learning classifier trained on expert-guided structural features to assess tryptophan (Trp) oxidation risks in the complementarity-determining regions (CDR) of 187 antibodies produced internally at Genentech. The model reveals a strong correlation between local negative electrostatic potential and Trp oxidation susceptibility. A simplified two-parameter model derived from these insights achieves 79% accuracy in classifying oxidation risk, compared to 84% accuracy with the full-feature classifier. Beyond our internal dataset, the two-parameter model successfully predicted oxidation risk for all CDR Trp sites in a blind subset of eight clinical-stage antibodies. In addition, we show that modulating the electrostatic potential around the Trp side-chains through distant charge-altering mutations can significantly reduce oxidation rates. In four out of five re-engineered antibodies, oxidation rates decreased by approximately 50%, while half of these maintained binding affinity. Finally, we demonstrate that this approach can guide multi-property optimization by balancing oxidation resistance and affinity in an anti-CD33 antibody. These results establish a strong link between local electrostatic environments and Trp oxidation susceptibility, and provide a practical framework for designing oxidation resistant biotherapeutics.

  • Open Access

    Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations

    by Joel Heisler, Daniel Kovner, Saeed Izadi, Jonathan Zarzar, Paul J. Carter

    The self-association of therapeutic antibodies can result in elevated viscosity and create problems in manufacturing and formulation, as well as limit delivery by subcutaneous injection. The high concentration viscosity of some antibodies has been reduced by variable domain mutations or by the addition of formulation excipients. In contrast, the impact of Fc mutations on antibody viscosity has been minimally explored. Here, we studied the effect of a panel of common and clinically validated Fc mutations on the viscosity of two closely related humanized IgG1, κ antibodies, omalizumab (anti-IgE) and trastuzumab (anti-HER2). Data presented here suggest that both Fab-Fab and Fab-Fc interactions contribute to the high viscosity of omalizumab, in a four-contact model of self-association. Most strikingly, the high viscosity of omalizumab (176 cP) was reduced 10.7- and 2.2-fold by Fc modifications for half-life extension (M252Y:S254T:T256E) and aglycosylation (N297G), respectively. Related single mutations (S254T and T256E) each reduced the viscosity of omalizumab by ~6-fold. An alternative half-life extension Fc mutant (M428L:N434S) had the opposite effect in increasing the viscosity of omalizumab by 1.5-fold. The low viscosity of trastuzumab (8.6 cP) was unchanged or increased by ≤2-fold by the different Fc variants. Molecular dynamics simulations provided mechanistic insight into the impact of Fc mutations in modulating electrostatic and hydrophobic surface properties as well as conformational stability of the Fc. This study demonstrates that high viscosity of some IgG1 antibodies can be mitigated by Fc mutations, and thereby offers an additional tool to help design future antibody therapeutics potentially suitable for subcutaneous delivery.


  • Open Access

    Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling

    by Eliott Park, Saeed Izadi

    In silico assessment of antibody developability during early lead candidate selection and optimization is of paramount importance, offering a rapid and material-free screening approach. However, the predictive power and reproducibility of such methods depend heavily on the selection of molecular descriptors, model parameters, accuracy of predicted structure models, and conformational sampling techniques. Here, we present a set of molecular surface descriptors specifically designed for predicting antibody developability. We assess the performance of these descriptors by benchmarking their correlations with an extensive array of experimentally determined biophysical properties, including viscosity, aggregation, hydrophobic interaction chromatography, human pharmacokinetic clearance, heparin retention time, and polyspecificity. Further, we investigate the sensitivity of these surface descriptors to methodological nuances, such as the choice of interior dielectric constant, hydrophobicity scales, structure prediction methods, and the impact of conformational sampling. Notably, we observe systematic shifts in the distribution of surface descriptors depending on the structure prediction method used, driving weak correlations of surface descriptors across structure models. Averaging the descriptor values over conformational distributions from molecular dynamics mitigates the systematic shifts and improves the consistency across different structure prediction methods, albeit with inconsistent improvements in correlations with biophysical data. Based on our benchmarking analysis, we propose six in silico developability risk flags and assess their effectiveness in predicting potential developability issues for a set of case study molecules.


  • Open Access

    Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody

    by Jing Dai, Saeed Izadi, Jonathan Zarzar, Patrick Wu, Angela Oh, Paul J. Carter

    Subcutaneous injection is the preferred route of administration for many antibody therapeutics for reasons that include its speed and convenience. However, the small volume limit (typically ≤2 mL) for subcutaneous delivery often necessitates antibody formulations at high concentrations (commonly ≥100 mg/mL), which may lead to physicochemical problems. For example, antibodies with large hydrophobic or charged patches can be prone to self-interaction giving rise to high viscosity. Here, we combined X-ray crystallography with computational modeling to predict regions of an anti-glucagon receptor (GCGR) IgG1 antibody prone to self-interaction. An extensive mutational analysis was undertaken of the complementarity-determining region residues residing in hydrophobic surface patches predicted by spatial aggregation propensity, in conjunction with residue-level solvent accessibility, averaged over conformational ensembles from molecular dynamics simulations. Dynamic light scattering (DLS) was used as a medium throughput screen for self-interaction of ~ 200 anti-GCGR IgG1 variants. A negative correlation was found between the viscosity determined at high concentration (180 mg/mL) and the DLS interaction parameter measured at low concentration (2-10 mg/mL). Additionally, anti-GCGR variants were readily identified with reduced viscosity and antigen-binding affinity within a few fold of the parent antibody, with no identified impact on overall developability. The methods described here may be useful in the optimization of other antibodies to facilitate their therapeutic administration at high concentration.


  • Open Access

    Molecular Surface Descriptors to Predict Antibody Developability

    by Eliott Park, Saeed Izadi

    Understanding the molecular surface properties of monoclonal antibodies (mAbs) is crucial for determining their function, affinity, and developability. Yet, robust methods to accurately represent the key structural and biophysical features of mAbs on their molecular surface are still limited. Here, we introduce MolDesk, a set of molecular surface descriptors specifically designed for predicting antibody developability characteristics. We assess the performance of these descriptors by directly benchmarking their correlations with an extensive array of in vitro and in vivo data, including viscosity at high concentration, aggregation, hydrophobic interaction chromatography (HIC), human pharmacokinetic (PK) clearance, Heparin retention time, and polyspecificity. Additionally, we investigate the sensitivity of these surface descriptors to methodological nuances, such as the choice of interior dielectric constant for electrostatic potential calculations, residue-level hydrophobicity scales, initial antibody structure models, and the impact of conformational sampling. Based on our benchmarking analysis, we propose six in silico developability rules that leverage these molecular surface descriptors and demonstrate their superior ability to predict the clinical progression of therapeutic antibodies compared to established models like TAP. 1


  • Open Access

    Abstract PR02: Factors modulating RAF dimerization downstream of RAS – A mechanistic overview

    by Jawahar Sudhamsu, Nicholas Liau, Timothy Wendorff, Saeed Izadi, Luca Gerosa

    The RAS-RAF pathway is one of the most commonly dysregulated in human cancers. The activation of this pathway is tightly regulated with appropriate spatial and temporal signaling cues. The central step in activation of this pathway is the dimerization of RAF kinases. Recent advances in biochemical, enzymatic and structural characterization of various multiprotein complexes in this pathway provide insight into various modes of RAF activity modulation. Kinase RAF and its substrate MEK exist as a pre-formed complex prior to pathway activation. Multiple factors prevent MEK phosphorylation by RAF in this pre-formed complex, including phosphorylation of a Serine residue N-terminal to the kinase domain, which enables 14-3-3 to trap RAF as a monomer. One of our intriguing findings is that cellular ATP exerts a negative regulatory effect on RAF kinase and stabilizes the inactive conformation of RAF monomer. We characterize this negative regulatory effect of ATP of RAF kinase structurally by solving a RAF-ATP complex and enzymology. Upon membrane recruitment of RAF by RAS-GTP, dephosphorylation of the above-mentioned serine residue in RAF occurs by a multiprotein complex composed of phosphatase PP1C, a scaffolding protein SHOC2 and RAS-GTP. We solved the structure of this RAS-SHOC2-PP1C complex and performed a thorough enzymatic analysis of this complex for RAF dephosphorylation. Our results show that RAF specificity is determined by SHOC2 and RAS GTP is responsible for spatial localization both inactive RAF and SHOC2/PP1C to the membrane. This dephosphorylation results in RAF being stabilized as a dimer by 14-3-3, which now binds to phospho-serine residues C-terminal to the kinase domain (S729 in BRAF) in 2 RAF molecules. We solve a structure of the RAF-14-3-3 complex. 14-3-3 induced RAF dimerization increases activity of RAF ~500 fold. Further, oncogenic mutations in RAF and MEK occur basally in tumors, and additional mutations are induced upon pathway inhibitor treatment in the clinic, especially for recent KRAS-G12C treatments. These mutations include RAF mutations that either activate or inactivate the kinase activity of the mutated RAF, but nevertheless result in pathway activation. Our data suggests that these mutations appear to tilt the RAF monomer-dimer equilibrium towards RAF dimer. The molecular mechanism of how the MEK mutations active the pathway in poorly understood. Biochemical and structural characterization of these mutations occurring in MEK kinases suggests that the mechanism of activation is also likely functioning via promoting RAF dimerization. This RAF dimer promotion appears to mechanistically work by relieving the negative regulatory effect of RAF by ATP to result in the “just-right” amount of pathway activation to sustain tumor growth. A comprehensive understanding of the various factors modulating RAF dimerization in the context of normal cell and cancer cells that depend on this pathway can pave the way for more precise interventions for treatment of cancers that depend on the RAS pathway. Citation Format: Jawahar Sudhamsu, Nicholas Liau, Timothy Wendorff, Saeed Izadi, Luca Gerosa. Factors modulating RAF dimerization downstream of RAS – A mechanistic overview [abstract]. In: Proceedings of the AACR Special Conference: Targeting RAS; 2023 Mar 5-8; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Res 2023;21(5_Suppl):Abstract nr PR02.